Enrolling
Fecal microbiota transplantation to reduce immune activation in ART-treated people living with HIV with low CD4/CD8 ratio
Learn MoreOngoing
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
Learn MoreReporting
A proof-of-concept study to assess the effect of recombinant human growth hormone on the size of the replication-competent viral reservoir in HIV-infected individuals on suppressive ART
Learn MoreCompleted
Impact of HIV infection and antiretroviral therapy on mucosal and systemic memory CD4 T cells
Learn MoreCompleted
A randomized, double blind, phase IIB study testing the efficacy and safety of AGS-004 on host control of HIV replication during analytical treatment interruption: Trial results
Learn MoreCompleted
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept study
Learn MoreCompleted
A phase II study testing the activity and safety of AGS-004 as an immunotherapeutic in successfully ART-treated subjects infected with HIV-1 in combination with ART followed by ART interruption: Trial results
Learn MoreCompleted
A pilot study (Phase I/II) testing the immunologic activity and safety of AGS-004, an autologous HIV immunotherapeutic, in HIV-infected adults on HAART: Trial results
Learn MoreCompleted
Use of valproic acid to purge HIV from resting CD4+ memory cells: Trial results
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
